All Insight, Analysis and Views

ViewPoints: Ardelyx cashes in on tenapanor despite some loose ends

Ref: ViewPoints Desk

Tags: ViewPoints Ardelyx End-stage renal disease Irritable Bowel Syndrome FDA Clinical Research (R&D) Corporate Affairs tenapanor

ViewPoints: Biogen sets its regulatory course for aducanumab

Ref: ViewPoints Desk

Tags: ViewPoints Biogen Dementia Clinical Research (R&D) Regulatory Affairs CTAD aducanumab

Friday Five – The pharma week in review (5 December 2019)

Ref: Friday Five Desk

Tags: Friday Five Clinical Research (R&D) Corporate Affairs Marketing & Sales Mergers & Acquisitions Regulatory Affairs

ViewPoints: Eli Lilly gives Loxo a broader remit

Ref: ViewPoints Desk

Tags: ViewPoints Lilly Loxo Oncology Clinical Research (R&D) Corporate Affairs

ViewPoints: Atreca tests the clinical waters for its drug discovery tech

Ref: ViewPoints Desk

Tags: ViewPoints Atreca Lung Cancer Clinical Research (R&D) Regulatory Affairs ATRC-101

ViewPoints: Neurocrine continues putting war chest to work

Ref: ViewPoints Desk

Tags: ViewPoints AbbVie Neurocrine Xenon Epilepsy FDA Clinical Research (R&D) Licensing Ingrezza Orilissa XEN901

ViewPoints: Millendo mounts its commercial prep in Prader-Willi

Ref: ViewPoints Desk

Tags: ViewPoints Millendo Therapeutics Atterocor Menopause Clinical Research (R&D) Corporate Affairs livoletide nevanimibe

ViewPoints: Biogen quietly backfills its long-term prospects

Ref: ViewPoints Desk

Tags: ViewPoints Biogen AstraZeneca Dementia Lupus FDA Clinical Research (R&D) Marketing & Sales Regulatory Affairs aducanumab BIIB059 anifrolumab gosuranemab

Physician Views snap poll – Asking rheumatologists five critical questions about AbbVie's Rinvoq

Ref: Physician Views Desk

Tags: Physician Views AbbVie Arthritis Marketing & Sales Medical Affairs Rinvoq

Spotlight On: Gene Therapy buying spree continues despite long-term questions about pricing

Ref: Spotlight On Desk

Tags: Spotlight On Astellas Audentes Therapeutics Corporate Affairs Mergers & Acquisitions